Retatrutide vs Mounjaro vs Ozempic: what's the difference?

What is the difference between retatrutide, Mounjaro, and Ozempic?

Retatrutide, Mounjaro, and Ozempic differ in three ways: the molecule inside each one, how many hormone signals the published papers map that molecule to, and whether any regulator has approved it. Ozempic is an approved medicine built on semaglutide, described in the literature as acting on GLP-1 (glucagon-like peptide-1, the fullness signal) alone. Mounjaro is an approved medicine built on tirzepatide, which the papers map to two signals, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide, the meal-and-insulin signal). Retatrutide is an experimental peptide the papers map to all three, adding glucagon. As of 2026, retatrutide is in Phase 3 trials and is approved in no country.

The short version is a key count. Semaglutide carries one key. Tirzepatide carries two. Retatrutide is built with three, and the third one is where the interest lies. Glucagon does not behave like the other two: it is the signal your liver listens for when food has stopped arriving and stored energy needs releasing. Adding it to a molecule that already speaks both mealtime signals is the question Phase 3 exists to answer.

Is retatrutide the same as Mounjaro?

Retatrutide is not the same molecule as Mounjaro. Mounjaro is a TGA- and FDA-approved prescription medicine containing tirzepatide, a 39-amino-acid peptide first characterised as a dual GIP and GLP-1 agonist (Coskun et al., Molecular Metabolism, 2018). Zepbound is a second FDA-approved medicine built on that same tirzepatide molecule, and as of 2026 Zepbound is not TGA-approved in Australia. Retatrutide is a separate experimental peptide, with a different amino-acid sequence, a different research code, and a third receptor system in its published profile.

Both compounds came out of Eli Lilly, which is exactly why the names get tangled. A shared laboratory is not a shared molecule. The pattern in the family tree is worth noticing, though: the locks never change. They are the gut-hormone signals your body has used after every meal of your life. What changes is the key. One receptor system, then two, now three.

Is Mounjaro the same molecule as Ozempic?

Mounjaro and Ozempic are different approved medicines with different active molecules. Ozempic and Wegovy contain semaglutide, which the literature maps to a single signal, GLP-1. Mounjaro and Zepbound contain tirzepatide, mapped to two, GLP-1 and GIP. The SURPASS-2 trial put the two molecules side by side in adults with type 2 diabetes over 40 weeks and recorded a 2.30-point change in HbA1c (a three-month blood-sugar marker) in the highest tirzepatide trial arm, against 1.86 points with semaglutide (Frias et al., New England Journal of Medicine, 2021).

Those numbers belong to the trial that produced them and nowhere else. SURPASS-2 measured two approved prescription medicines, in diagnosed patients, under clinical supervision, against one blood marker chosen before the trial began. That is a narrow question, answered carefully. It is not a league table of molecules.

Evidence limits

What has the research not shown yet?

Lining those two percentages up and declaring a winner is the most natural thing in the world to do, and it is the one thing the evidence cannot support. Different trials. Different lengths — 48 weeks against 72. Different people, recruited under different rules. A percentage only means something while it is still attached to the study that produced it.

A third figure gets quoted alongside them. In a smaller imaging study of 98 adults whose liver fat started at 10% or higher, the highest retatrutide trial arm averaged an 82.4% drop in liver fat at 24 weeks (Sanyal et al., Nature Medicine, 2024). One study, one trial arm, 24 weeks — interesting, and far too narrow to build a conclusion on. TRIUMPH and TRANSCEND, the Phase 3 programmes that could answer the larger question, had published no results as of 2026.

Is research material a substitute for Mounjaro or Ozempic?

Research-use-only material is not a substitute for Mounjaro or Ozempic. Mounjaro and Ozempic are approved prescription medicines, dispensed and supervised. Laboratory reference material is not those medicines, not a cheaper route to them, and not for human or animal use. Where a research compound and a medicine happen to share a molecule, that shared identity is a fact of chemistry and nothing more. Retatrutide has no approved medicine anywhere as of 2026, so there is nothing for laboratory material to stand in for.

Price questions land in the same place. What laboratory material costs is a question about synthesis — how long the amino-acid chain is, how pure the finished powder runs, and how much testing sits behind that purity number. It is never a comparison with what a pharmacy charges. Form Laboratories lists retatrutide reference material as freeze-dried laboratory stock with lot-matched paperwork. Reading that paperwork is a skill of its own — what a certificate of analysis records, what a third-party report proves, how a batch stays traceable — and the quality and verification hub walks through it.